|
|
| Oncologie > Etude de marché sectorielle |
| Pipeline Insight: Breast Cancer - A diverse and increasingly crowded pipeline |
|
|
|
|
€ 9 120,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Juillet 2006 |
Taille du document : |
247 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (1) |
|
|
|
| 74 pages | Janvier 2002 | Anglais
|
|
|
| Main
focus: |
cancer,breast cancer,prostate cancer,lung cancer,...,...
|
| Research
focus: |
market definition,market outlook |
| Geographic
focus: |
canada,france,australia |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Annual Spending on Cancer Drugs per Person
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
Classes of Drugs Used to Treat Breast Cancer
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
MarketWatch: Cancer
28 pages | Novembre 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
170,00 €
|
| |
| |
The Cancer Outlook 2000
128 pages | Septembre 2000 |
Driven by the cytotoxic, adjunct and innovative drug classes, the cancer market grew by 16% in 1999 to a global value of almost $19bn, and is now poised on the verge of a period of significant exp |
955,00 €
|
| |
| |
Chinese Markets for Cancer Treatment Drugs
272 pages | Septembre 2005 |
China's demand for cancer treatmen drugs has grown at a fast pace in the past decade.
In the next five years, both production and demand will continue to grow.
This new study examines China's ec |
2 835,00 €
|
| |
| |
MarketWatch: Cancer
29 pages | Octobre 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
170,00 €
|
| |
| |
Country Survival Rates for Breast Cancer
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
Stakeholder Insight: Pancreatic Cancer - Gold Standard Gemcitabine Waiting to be Challenged
259 pages | Décembre 2004 |
IntroductionPancreatic adenocarcinoma is the fifth leading cancer-related cause of death and is thus a major health issue in the developed world.
Its aggressive nature and resistance to conventiona |
12 160,00 €
|
| |
| |
MarketWatch: Cancer
27 pages | Mai 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
160,00 €
|
| |
| |
MarketWatch: Cancer
30 pages | Juin 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
160,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Pipeline Insight: Breast Cancer - A diverse and increasingly crowded pipeline |
|
|
Introduction
Breast cancer is the leading cause of cancer-related mortality among women worldwide. In 2006, more than 447,000 cases of the disease are expected to be diagnosed in the seven major pharmaceutical markets. High unmet needs still persist for this tumor type. Despite recent drug approvals in the adjuvant and metastatic setting, the overall survival remains below five years.
Scope
*Overview of breast cancer and the current treatment options, including profiles and analysis of existing drugs
*Insightful analysis of clinical trial data for late-phase drugs in development for breast cancer
*Future global sales of key pipeline drugs for breast cancer to 2016, including their clinical/research and commercial attractiveness
*Datamonitor's assessment of the clinical and commercial potential of the drugs currently in development for breast cancer
Highlights
There are at least 144 candidates in the breast cancer pipeline of which, 26% are molecular targeted therapeutics (MTTs). Due to the cytostatic nature of several MTTs, significant tumor regressions will likely be achieved when combined with cytotoxics. As cytotoxics comprise one-third of the pipeline, they will remain the backbone of treatment.
Datamonitor believes Genentech/Roche's Avastin (bevacizumab) will earn blockbuster status within the breast cancer market. Unlike Herceptin, Avastin is not limited to HER-2 positive tumors and will have a major impact on first-line metastatic disease. Avastin will dominate the breast cancer market with 2016 sales approaching $1.5bn.
GlaxoSmithKline's' Tykerb (lapatinib) will expand treatment options for HER-2 positive, Herceptin-refractory, locally advanced and metastatic patients, with approval likely by early-2007. As an estimated 40% of patients are Herceptin-refractory, Tykerb's sales could reach over $500m by 2016 in this setting alone.
Reasons to Purchase
*Assess opportunities and risks in the breast cancer market by analyzing the clinical and commercial attractiveness of key agents
*Evaluate the potential of your product in the breast cancer market by examining key pipeline drug sales forecasts
*Determine the commercial impact of new molecular-targeted agents entering the breast cancer market and their effects on current treatment paradigms
|
|
Pipeline Insight: Breast Cancer - A diverse and increasingly crowded pipeline
|
|
|
PPLSEN
|
|
|
|
|
